

THE 1984 DEUEL CONFERENCE ON LIPIDS

July 12, 1983

Advisory Board

Edwin L. Bierman, *Chairman*
Department of Medicine, RG-26
University of Washington
Seattle, Washington 98195
(Phone: 206/543-3159)

Erol R. Diller, 1985
Howard A. Eder, 1986
Daniel Steinberg, 1987
Scott M. Grundy, 1988
Julian B. Marsh, 1989

Frank T. Lindgren, *Treasurer*
Donner Laboratory
University of California
Berkeley, California 94720
(Phone: 415/486-4604)

Richard J. Havel, *Local Arrangements*
Cardiovascular Research Institute 1315M
University of California
San Francisco, California 94143
(Phone: 415/666-2226)

Ralph T. Holman, *Funding*
The Hormel Institute
University of Minnesota
801 16th Avenue N.E.
Austin, Minnesota 55912
(Phone: 507/433-8804)

Program Committee
William R. Hazzard, *Chairman*
Blalock 1007

Johns Hopkins Hospital
Baltimore, Maryland 21205
(Phone: 301/955-8131)

Alexander V. Nichols, 1985
Alan M. Fogelman, 1986

Dr. Robert C. Hockett
Research Director
The Council for Tobacco
Research-U.S.A., Inc.
110 East 59th Street
New York, NY 10022

Dear Dr. Hockett:

The 1984 Deuel Conference on Lipids has been tentatively set for March 7-10 at the Holiday Inn in Napa Valley, California. Dr. William R. Hazzard, Program Chairman, has announced a preliminary program as follows:

Theme: "Modulation of Human Lipoprotein Metabolism"

Sessions are tentatively planned to include: **genetic factors**, concentrating on hyperapobetalipoproteinemia/familial combined hyperlipidemia and the regulation of apo B synthesis and secretion; **hormonal factors**, notably insulin as related to abnormalities in lipoprotein metabolism and atherogenesis, and diabetes and sex steroid metabolism as related to the sex differential in atherogenesis and longevity; and **pharmacologic factors**, including the effectiveness of maximal, combined drug therapy (e.g., mevinolin and colestipol, nicotinic acid and cholestyramine), the relationship of such maximal hypolipidemic therapy to atherosclerosis regression, and the outcome of the Lipid Research Clinics Coronary Primary Prevention Trial (to be announced in January 1984). The current leaders in each area will be the speakers.

Because of past support of The Council for Tobacco Research for Deuel Conferences, we are informing you of the forthcoming program for the 1984 conference and again soliciting your financial support. However, due to the conference size limitations, it has become necessary to restrict supporting firms to two participants, with a minimum donation of \$1000 per attendee.

As in the past, the Deuel Conference maintains an informal atmosphere, encourages free and open discussion, and is a forum for the presentation of new and unpublished data in rapidly developing new fields of research.

July 11, 1983
Page two

For your information, I enclose a copy of last year's program and a brief description of the Deuel Conference. We would be grateful for your early decision on support for the 1984 conference. If you are able to support the conference, please make the check payable to "The 1984 Deuel Conference" and send it to my attention at The Hormel Institute. We would also appreciate receiving the name of your attendee(s) as soon as possible so program and registration materials may be forwarded.

Sincerely,



Ralph T. Holman
Chairman, Funding Committee

RTH:ds

cc: Richard Havel, Chairman, Local Arrangements
William Hazzard, Chairman, Program Committee

Enclosures